Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

Table 1 Overall Response Rates (IRC)

Best response, n (%)	PTCL-NOS	AITL	ALK-1–Negative ALCL
Best response, n (%)	(n = 69)	(n = 27)	(n = 21)
ORR	20 (29)	8 (30)	5 (24)
CR/CRu	10 (14)	5 (19)	4 (19)
PR	10 (14)	3 (11)	1 (5)
SD	16 (23)	9 (33)	5 (24)
Disease control (ORR + SD90)	34 (49)	12 (44)	8 (38)
PD/NE^a	33 (48)	10 (37)	11 (52)

Abbreviations: AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, CR/CRu confirmed/unconfirmed complete response, IRC Independent Review Committee, NE not evaluable, ORR objective response rate, PD progressive disease, PR partial response, PTCL-NOS peripheral T-cell lymphoma–not otherwise specified, SD stable disease, SD90 SD for ≥ 90 days.
^aInsufficient efficacy data to determine response because of early termination.

ISSN: 1756-8722